The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients.
Lesi sidakamizwa, i-Aduhelm, ukumfakelwa nyangazonke ngentengo engu- $ 56,000 ngonyaka, samukelwe kuleli sonto yize kunobufakazi obubuthakathaka bokuthi busiza iziguli. ...